Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
ChinaBio® Survey Finds Rising Insider Optimism for China Healthcare
Barclays follows a portfolio of healthcare stocks that are traded in ex-China markets, mostly Hong Kong. Jason Mann, MD, PhD, Barclays’ analyst for China healthcare, believes the rise in sentiment shows that difficulties caused by government policy – which means mainly mandated price reductions – are now largely behind us.
One year ago, Barclays was not so optimistic. Its take on the sector was that most company’s stock prices were overpriced, compared to industry norms. And as the ChinaBio® survey pointed out, industry insiders were more pessimistic than analysts, who were not directly involved in day-to-day decisions. That discrepancy caused Dr. Mann to view the stocks skeptically.
All of that skepticism is now in the past. The survey shows that insiders are increasingly optimistic, and Barclays expects outsized results from smaller healthcare companies with increasing revenues and from larger, national-scale companies that will profit from increasing consolidation.
Disclosure: ChinaBio® has a business relationship with Barclays Bank.